New data on duration of protection afforded by natural SARS-CoV-2 infection

In a recent study posted to the medRxiv* preprint server, researchers investigated the immune protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) natural reinfection.

The currently available coronavirus disease 2019 (COVID-19) vaccines played a critical role in curbing the number of COVID-19-related hospitalizations and mortalities. However, their waning immune efficacy has led to an increased number of SARS-CoV-2 reinfections which has further limited their usefulness in curbing the COVID-19 pandemic.

Study: Duration of immune protection of SARS-CoV-2 natural infection against reinfection in Qatar. Image Credit:Study: Duration of immune protection of SARS-CoV-2 natural infection against reinfection in Qatar. Image Credit: NIAID

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

About the study

In the present study, researchers explored the duration of protection provided by natural infection, as well as the impact of viral immune evasion on this duration and the robustness of the protection against severe SARS-CoV-2 infection.

The team performed a retrospective study using randomized target trials using COVID-19 data related to laboratory testing, COVID-19 vaccination, and associated hospitalization and death. In this study, all SARS-CoV-2 data from healthcare facilities, including PCR tests and rapid antigen tests, was collected.

The team compared the incidence of either SARS-CoV-2 infection or severe, critical, or fatal COVID-19 disease among the primary-infection cohort comprising individuals reporting a primary COVID-19 infection diagnosed before the vaccination, a control cohort including persons who are infection-naive, and the infection-naive cohort including unvaccinated individuals.

Individuals belonging to the primary-infection cohort were matched to individuals from the infection-naive cohort according to gender, age group, nationality, and the number of comorbidities. Individual matching was also performed as per the calendar week when the SARS-CoV-2 testing was conducted. The monitoring of each matched pair began when an individual from the primary-infection cohort reached 90 days following diagnosis.

The pre-Omicron reinfection study estimated the efficacy of a pre-Omicron primary infection against pre-Omicron reinfection, and the Omicron reinfection study assessed the efficacy of a pre-Omicron primary infection against an Omicron lineage reinfection. Furthermore, the SARS-CoV-2 severity reinfection study evaluated the efficacy of a primary SARS-CoV-2 infection against either severe, critical, or fatal reinfection, irrespective of the causative variant. Any individual who reported a primary infection from 28 February 2020 to 30 November 2021 was included in the primary-infection group. Any individual who tested SARS-CoV-2-negative throughout this period was included in the infection-naive group. The study outcomes included an infection diagnosis and the occurrence of either severe, critical, or fatal SARS-CoV-2 infection. 

Results

The study results showed that among the 1,806 reinfections detected in the primary-infection group throughout the follow-up period of the pre-Omicron reinfection study, six individuals experienced severe COVID-19 while one patient succumbed to the infection. The infection-naive cohort included 11,957 cases, among which 297 cases experienced severe, 19 critical, and 12 fatal COVID-19. The primary-infection and the infection-naive cohorts reported 1.7% and 9.6% cumulative infection incidence in 15 months post-primary infection.

The team observed that pre-Omicron primary infection was 85.5% effective against pre-Omicron reinfection. Moreover, this efficacy increased to 90.5% in the seventh month following the primary infection, which subsequently decreased to almost 70% by the 16th-month post-primary infection. The team also noted that the efficacy reduced to 50% and less than 10% in the 22nd and the 32nd month. Furthermore, the efficacy of the primary pre-Omicron infection was 98.0% against severe, critical, and fatal COVID-19 caused by reinfection with a pre-Omicron variant.

The Omicron reinfection study showed that among the 7995 reinfections found in the primary-infection cohort throughout the follow-up period, five individuals experienced severe COVID-19. The infection-naive cohort included 12,230 cases, among which 26 cases experienced severe, seven critical, and five fatal COVID-19 infections. The primary infection and the infection-naive cohorts reported 6.8% and 10.4% cumulative infection incidence in 165 days after the beginning of the follow-up period.

The team observed that pre-Omicron primary infection was 38.1% effective against Omicron reinfection. Moreover, the efficacy was almost 60% against Omicron reinfection for individuals who tested positive for a primary infection between 1 June 2021 and 30 November 2021. However, this effectiveness was 17.0% and 50% for individuals who reported primary infection between 1 December 2020 and 28 February 2021 and before 31 August 2020, respectively. Furthermore, the efficacy of the primary pre-Omicron infection was 88.6% against severe, critical, and fatal COVID-19 caused by Omicron reinfection.

The COVID-19 severity reinfection study showed that among the 7082 reinfections in the primary-infection cohort, nine and one individual had severe and fatal COVID-19, respectively. The infection-naive cohort included 21,645 cases, among which 315 experienced severe, 25 critical, and 18 fatal COVID-19. The primary-infection and the infection-naive cohorts reported 0.0% and 0.21% cumulative infection incidence 15 months post-primary infection. The efficacy of the primary infection was 97.3% against severe, critical, and fatal COVID-19 caused by any variant.

Overall, the study findings showed that natural SARS-CoV-2 infection provided robust protection against reinfection for over 14 months after the primary infection.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:
  • Preliminary scientific report. Duration of immune protection of SARS-CoV-2 natural infection against reinfection in Qatar, Hiam Chemaitelly, Nico Nagelkerke, Houssein Ayoub, Peter Coyle, Patrick Tang, HADI M. YASSINE, Hebah A. Al-Khatib, Maria K. Smatti, Mohammad R. Hasan, Zaina Al-Kanaani, Einas Al-Kuwari, Andrew Jeremijenko, Anvar Hassan Kaleeckal, Ali Nizar Latif, Riyazuddin Mohammad Shaik, Hanan F. Abdul-Rahim, Gheyath Nasrallah, Mohamed Ghaith Al-Kuwari, Adeel A Butt, Hamad Eid Al-Romaihi, Mohamed H. Al-Thani, Abdullatif Al-Khal, Roberto Bertollini, Laith J Abu-Raddad, medRxiv 2022.07.06.22277306, DOI: https://doi.org/10.1101/2022.07.06.22277306https://www.medrxiv.org/content/10.1101/2022.07.06.22277306v1
  • Peer reviewed and published scientific report. Chemaitelly, Hiam, Nico Nagelkerke, Houssein H Ayoub, Peter Coyle, Patrick Tang, Hadi M Yassine, Hebah A Al-Khatib, et al. 2022. “Duration of Immune Protection of SARS-CoV-2 Natural Infection against Reinfection.” Journal of Travel Medicine 29 (8). https://academic.oup.com/jtm/article/29/8/taac109/6731972.

Article Revisions

  • Jun 6 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Bhavana Kunkalikar

Written by

Bhavana Kunkalikar

Bhavana Kunkalikar is a medical writer based in Goa, India. Her academic background is in Pharmaceutical sciences and she holds a Bachelor's degree in Pharmacy. Her educational background allowed her to foster an interest in anatomical and physiological sciences. Her college project work based on ‘The manifestations and causes of sickle cell anemia’ formed the stepping stone to a life-long fascination with human pathophysiology.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Kunkalikar, Bhavana. (2023, June 06). New data on duration of protection afforded by natural SARS-CoV-2 infection. News-Medical. Retrieved on November 21, 2024 from https://www.news-medical.net/news/20220711/New-data-on-duration-of-protection-afforded-by-natural-SARS-CoV-2-infection.aspx.

  • MLA

    Kunkalikar, Bhavana. "New data on duration of protection afforded by natural SARS-CoV-2 infection". News-Medical. 21 November 2024. <https://www.news-medical.net/news/20220711/New-data-on-duration-of-protection-afforded-by-natural-SARS-CoV-2-infection.aspx>.

  • Chicago

    Kunkalikar, Bhavana. "New data on duration of protection afforded by natural SARS-CoV-2 infection". News-Medical. https://www.news-medical.net/news/20220711/New-data-on-duration-of-protection-afforded-by-natural-SARS-CoV-2-infection.aspx. (accessed November 21, 2024).

  • Harvard

    Kunkalikar, Bhavana. 2023. New data on duration of protection afforded by natural SARS-CoV-2 infection. News-Medical, viewed 21 November 2024, https://www.news-medical.net/news/20220711/New-data-on-duration-of-protection-afforded-by-natural-SARS-CoV-2-infection.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Leritrelvir shows high efficacy against SARS-CoV-2 protease mutations